{"filing":{"accession_number":"0001193125-26-312391","cik":"0001544227","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"d107304d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526312391/d107304d8k.htm"},"events":[{"id":19475,"run_id":17531,"accession_number":"0001193125-26-312391","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Tempest entered into a material strategic collaboration agreement with Senlang Biotechnology for product development and an investigator-initiated trial of TPST-4003 in China, including development fees, data rights, and an exclusive option for Senlang to negotiate a license for China rights. The agreement represents a significant operational and strategic milestone advancing the company's lead product candidate into first-in-human studies.","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18572,"accession_number":"0001193125-26-312391","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tempest entered into a material collaboration agreement with Senlang Biotechnology for product development and an investigator-initiated trial of TPST-4003 in China. The agreement includes development fees ($1.5–$2.0 million per product), data rights, and grants Senlang an exclusive option to negotiate a license for China rights. While this is a strategic partnership advancing a lead product candidate into first-in-human studies, it does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control), nor does it fit neatly into other specific categories. The collaboration is clearly material to investors as it represents a significant operational and strategic milestone for the company's pipeline development, but the event is best classified as an operational partnership rather than a financial or governance matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:07:22.484834+00:00","company_name":"","ticker":null,"filing_date":""},{"id":18573,"accession_number":"0001193125-26-312391","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a strategic development collaboration between Tempest and Senlang Biotechnology for TPST-4003, a next-generation in vivo CAR-T candidate. The agreement includes an investigator-initiated trial in China with first patient dosing expected in Q4 2026, and grants Senlang an exclusive option to negotiate a definitive license agreement for TPST-4003 in China. This is a material operational and strategic partnership advancing a lead product candidate into first-in-human studies, but does not fit the specific categories of M\u0026A activity, debt issuance, or other defined event types—it is a material collaboration and development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:07:22.484834+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18572,"accession_number":"0001193125-26-312391","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tempest entered into a material collaboration agreement with Senlang Biotechnology for product development and an investigator-initiated trial of TPST-4003 in China. The agreement includes development fees ($1.5–$2.0 million per product), data rights, and grants Senlang an exclusive option to negotiate a license for China rights. While this is a strategic partnership advancing a lead product candidate into first-in-human studies, it does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control), nor does it fit neatly into other specific categories. The collaboration is clearly material to investors as it represents a significant operational and strategic milestone for the company's pipeline development, but the event is best classified as an operational partnership rather than a financial or governance matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:07:22.484834+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-07-22"},{"id":18573,"accession_number":"0001193125-26-312391","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a strategic development collaboration between Tempest and Senlang Biotechnology for TPST-4003, a next-generation in vivo CAR-T candidate. The agreement includes an investigator-initiated trial in China with first patient dosing expected in Q4 2026, and grants Senlang an exclusive option to negotiate a definitive license agreement for TPST-4003 in China. This is a material operational and strategic partnership advancing a lead product candidate into first-in-human studies, but does not fit the specific categories of M\u0026A activity, debt issuance, or other defined event types—it is a material collaboration and development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:07:22.484834+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-07-22"}]}